Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2005 1
2006 4
2007 2
2008 3
2009 4
2010 5
2011 6
2012 8
2013 7
2014 7
2015 6
2016 5
2017 8
2018 12
2019 10
2020 16
2021 20
2022 10
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Beksac M, Eikema DJ, Koster L, Hulin C, Poiré X, Hamladji RM, Gromek T, Bazarbachi A, Ozkurt ZN, Pabst T, Ben Othman T, Finke J, Pirogova O, Wu D, Hayat A, Hilgendorf I, Tholouli E, de Wreede LC, Schönland S, Garderet L, Drozd-Sokolowska J, Raj K, Hayden PJ, Yakoub-Agha I, McLornan DP. Beksac M, et al. Among authors: hulin c. Bone Marrow Transplant. 2024 Apr;59(4):526-533. doi: 10.1038/s41409-023-02160-8. Epub 2024 Jan 31. Bone Marrow Transplant. 2024. PMID: 38297040 Free PMC article.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: hulin c. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Rosiñol L, Hebraud B, Oriol A, Colin AL, Ríos Tamayo R, Hulin C, Blanchard MJ, Caillot D, Sureda A, Hernández MT, Arnulf B, Mateos MV, Macro M, San-Miguel J, Belhadj K, Lahuerta JJ, Garelik MB, Bladé J, Moreau P. Rosiñol L, et al. Among authors: hulin c. Front Oncol. 2023 Nov 2;13:1197340. doi: 10.3389/fonc.2023.1197340. eCollection 2023. Front Oncol. 2023. PMID: 38023148 Free PMC article.
Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.
Faganello D, Bertrand A, Meunier P, Avouac J, Toussirot E, Coury F, Seror R, Le Mélédo G, Germain V, Dellal A, Shima D, Hulin C, Prati C, Schaeverbeke T, Richez C, Truchetet ME, Kostine M. Faganello D, et al. Among authors: hulin c. Rheumatology (Oxford). 2024 Mar 1;63(3):787-790. doi: 10.1093/rheumatology/kead187. Rheumatology (Oxford). 2024. PMID: 37540112
Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.
Beksac M, Iacobelli S, Koster L, Cornelissen J, Griskevicius L, Rabin NK, Stoppa AM, Meijer E, Mear JB, Zeerleder S, Mayer J, Fenk R, Fegueux N, Chevallier P, Konirova E, Snowden JA, Engelhardt M, Orchard K, Hulin C, Schaap N, Sossa C, Elmaagacli A, McLornan DP, Hayden PJ, Schönland S, Yakoub-Agha I. Beksac M, et al. Among authors: hulin c. Bone Marrow Transplant. 2023 Sep;58(9):1065. doi: 10.1038/s41409-023-02014-3. Bone Marrow Transplant. 2023. PMID: 37316543 No abstract available.
[Access and safety of dexamethasone in multiple myeloma patients].
Slimano F, Tournamille JF, Bardin C, Madelaine I, Hulin C, Moreau P, Rioufol C. Slimano F, et al. Among authors: hulin c. Bull Cancer. 2023 Jun;110(6):731-733. doi: 10.1016/j.bulcan.2023.05.001. Epub 2023 May 22. Bull Cancer. 2023. PMID: 37225617 French. No abstract available.
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.
Beksac M, Iacobelli S, Koster L, Cornelissen J, Griskevicius L, Rabin NK, Stoppa AM, Meijer E, Mear JB, Zeerleder S, Mayer J, Fenk R, Fegueux N, Chevallier P, Konirova E, Snowden JA, Engelhardt M, Orchard K, Hulin C, Schaap N, Sossa C, Elmaagacli A, McLornan DP, Hayden PJ, Schönland S, Yakoub-Agha I. Beksac M, et al. Among authors: hulin c. Bone Marrow Transplant. 2023 Aug;58(8):916-923. doi: 10.1038/s41409-023-01999-1. Epub 2023 May 9. Bone Marrow Transplant. 2023. PMID: 37160942
133 results